Download PDF
Planta Medica Letters 2016; 3(01): e14-e16
DOI: 10.1055/s-0035-1568355
Letter
Georg Thieme Verlag KG Stuttgart · New York

Antiproliferative Butyrolactones from Mezilaurus crassiramea

Danilo Tófoli
1   Instituto de Química, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil
,
Laura Alves Verão Martins
2   Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil
,
Maria de Fátima Cepa Matos
2   Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil
,
Walmir Silva Garcez
1   Instituto de Química, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil
,
Fernanda Rodrigues Garcez
1   Instituto de Química, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil
› Author Affiliations
Further Information

Publication History

received 14 August 2015
revised 14 August 2015

accepted 15 January 2016

Publication Date:
11 February 2016 (online)

   Permissions and Reprints

Abstract

Bioassay-guided fractionation of the ethanol extract from the leaves of Mezilaurus crassiramea, which was toxic to Artemia salina larvae, afforded 3′-acetylrubrenolide (1), 2′,3′-diacetylrubrenolide (2), and rubrenolide (3) from the active dichloromethane soluble fraction. Compound 1 is new, while 2 and 3 are first reported from a natural source and in the Mezilaurus genus, respectively. Compound 3 showed significant cytotoxicity against UACC-62, MCF-7, HT-29, and PC-3 human cancer cell lines, with GI50 values ranging from 3.3 to 9.9 µg/mL, while 1 and 2 exhibited marginal activities against at least five of the six investigated cell lines. The structures of 1–3 were established on the basis of 1D- and 2D-nuclear magnetic resonance analyses, high-resolution electrospray ionization mass spectrometry data and specific optical rotation values.

Key words

Mezilaurus crassiramea - Lauraceae - γ-lactones - rubrenolide - cytotoxicity

Supporting Information

 

  • References

  • 1 Alves FM, Souza VC. Two new species of Mezilaurus (Lauraceae) from Brazil. Brittonia 2012; 64: 257-262
    CrossrefPubMedGoogle Scholar
  • 2 van der Werff H. A revision of Mezilaurus (Lauraceae). Ann Mo Bot Gard 1987; 74: 153-182
    CrossrefPubMedGoogle Scholar
  • 3 Alcântara JM, Yamaguchi KKL, Veiga-Junior VF. Composição de óleos essenciais de Dicypellium manausense, Mezilaurus duckei, Mezilaurus itauba e Pleurothyrium vasquezii, quatro espécies amazônicas da família Lauraceae. B Latinoam Caribe Pl 2013; 12: 469-475
    PubMedGoogle Scholar
  • 4 Yanez XR, de Diaz AMP, Diaz DPP. Neolignans from Mezilaurus itauba . Phytochemistry 1986; 25: 1953-1956
    CrossrefPubMedGoogle Scholar
  • 5 Silva R, Nagem TJ, Mesquita AAL, Gottlieb OR. γ-Lactones from Mezilaurus synandra . Phytochemistry 1983; 22: 772-773
    CrossrefPubMedGoogle Scholar
  • 6 Franca NC, Gottlieb OR, Coxon DT. Rubrenolide and rubrynolide: an alkene-alkyne pair from Nectandra rubra . Phytochemistry 1977; 16: 257-262
    CrossrefPubMedGoogle Scholar
  • 7 Rodrigues AMS, Theodoro PNET, Eparvier V, Basset C, Silva MRR, Beauchêne J, Espíndola LS, Stien D. Search for antifungal compounds from the wood of durable tropical trees. J Nat Prod 2010; 73: 1706-1707
    CrossrefPubMedGoogle Scholar
  • 8 Thijs L, Zwanenburg B. Rubrenolide, total synthesis and revision of its reported stereochemical structure. Tetrahedron 2004; 60: 5237-5252
    CrossrefPubMedGoogle Scholar
  • 9 Madda J, Khandregula S, Bandari SK, Kommu N, Yadav JS. Stereoselective total synthesis of rubrenolide and rubrynolide. Tetrahedron Asymmetry 2014; 25: 1494-1500
    CrossrefPubMedGoogle Scholar
  • 10 Meyer BN, Ferrigni NR, Putnam JE, Jacobsen LB, Nichols DE, McLaughlin JL. Brine shrimp: a convenient general bioassay for active-plant constituents. Planta Med 1982; 45: 31-34
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-1112
    CrossrefPubMedGoogle Scholar
  • 12 Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J, Boyd M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991; 83: 757-766
    CrossrefPubMedGoogle Scholar